PATENT CLAIM ANALYSIS

Application Number: 15759888
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "262100"]

Abstract:
The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Y are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases/injuries associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Sträussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Claim (Index 19):
A method of treating cancer in a mammal in need thereof, which comprises: administering to such mammal a therapeutically effective amount of\n a) a compound of Formula (I), as described in  claim 1  or a pharmaceutically acceptable salt thereof; and b) at least one anti-neoplastic agent.

Metadata:
- Claim Count in Document: 6.0
- Percentile: 90.0
- Lexical Diversity: 2.21053
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13637127', '16312061', '13859569', '14418484', '14458062']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7867548094777209
- 35 USC 102 Novelty (BERT): 0.5757480647214667
- Combined Prediction Score: 0.7656541350020954
- Mean Citation Score: 412.886896
- Max Citation Score: 503.5842
- Similarity Product: 344.17473329343795

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test